Drug Information request response for canagliflozin - A physician at a local clinic calls the pharmacy after seeing a patient who was newly diagnosed with Type II diabetes and is at an elevated risk for cardiovascular disease. The physician is looking to start a medication for the patient and has seen some material regarding SGLT2 inhibitors recently. The physician would like to know if the medication canagliflozin would be beneficial to lower the patients cardiovascular disease risk while also treating their diabetes. Would you recommend this for the patient and are there any side effects to be aware of especially from clinical trials?
a) Yes, recommend for cardiovascular benefits; No significant side effects reported.
b) No, not recommended for cardiovascular benefits; High risk of side effects reported.
c) Yes, recommend for cardiovascular benefits; Some side effects reported, monitor closely.
d) No information available; Cannot recommend.